poisar

Stocks · News reference

This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

BenzingaAvi Kapoor

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncResearchandmarkets.Com

    Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity

    Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.

  2. The Motley FoolSara Appino

    Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE?

    VanEck Biotech ETF (BBH) offers lower costs (0.35% expense ratio) and concentrated exposure to 25 large-cap biotech leaders, outperforming Invesco Biotechnology & Genome ETF (PBE) over the past year. However, PBE delivers higher dividend income (1.3% yield) and slightly better five-year returns through a multifactor selection strategy. BBH is ideal for cost-conscious momentum investors, while PBE suits those seeking income and a diversified factor-driven approach.